Experimental combo targets Tough-to-Treat leukemia
NCT ID NCT02787369
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called ACY-1215 (ricolinostat) combined with either ibrutinib or idelalisib in people whose chronic lymphocytic leukemia has returned after prior treatment. The main goal is to find a safe dose, while also checking if the combination helps shrink cancer or delay its growth. Only 3 participants were enrolled, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ricolinostat (ACY-1215) combined with ibrutinib or idelalisib
- What this could lead to
- If successful, this could point toward a new combination treatment option for patients with relapsed chronic lymphocytic leukemia.
- What could go wrong
- This is a very early, small Phase 1 trial with only 3 participants, so results may not apply broadly. The combination may cause unexpected side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CHRONIC LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States